What could we learn from the sub-analysis of a single nation cohort in a worldwide study? Lessons from the results observed in the Italian cohort of the GO-MORE trial

Authors :: Giacomelli, R.
Ruscitti, P.
Bombardieri, S.
Cuomo, G.
Vita, S. D.
Galeazzi, M.
Mecchia, M.
Lagana, B.
Versace, F.
Cantini, F.
Gerli, R.
Grassi, W.
Ferraccioli, G.
Migliore, A.
Valesini, G.
Minisola, G.
Paolazzi, G.
Sabbadini, M. G.
Sante, G. D.
Puttini, P. S.
Scarpellini, M.
Pellerito, R.
Bianchi, G.
Pozzi, M. R.
Triolo, G.
Iacono, D.
Foti, R.
Varcasia, G.
Amato de Paulis
Rocchetta, P. A.
Liakouli, V.
Cipriani, P.
Giacomelli, R
Ruscitti, P.
Bombardieri, S.
Cuomo, G
Vita, S. D.
Galeazzi, M
Mecchia, M.
Lagana, B
Versace, F
Cantini, F
Gerli, R
Grassi, W
Ferraccioli, G.
Migliore, A
Valesini, G
Minisola, G
Paolazzi, G
Sabbadini, M. G.
Sante, G. D.
Puttini, P. S.
Scarpellini, M.
Pellerito, R
Bianchi, G
Pozzi, M. R.
Triolo, G.
Iacono, D.
Foti, R.
Varcasia, G.
De Paulis, A.
Rocchetta, P. A.
Liakouli, V.
Cipriani, P.
Source :: Scopus-Elsevier
Abstract: GO-MORE Trial investigated the use of Golimumab (GLM) in 3280 rheumatoid arthritis (RA) patients worldwide. At present, the burden of arthritis is greater in poorer countries than in developed countries due to socioeconomic disparities, thus suggesting the usefulness of subgroup investigations. We aimed to evaluate GLM as add-on therapy for RA patients in the Italian cohort of GO-MORE trial and compared the clinical characteristics between Italian patients and the enrolled patients worldwide.

Tools